Prostate implant evaluation using tumour control probability--the effect of input parameters.
暂无分享,去创建一个
Annette Haworth | Martin Ebert | David Waterhouse | D. Waterhouse | M. Ebert | A. Haworth | David Joseph | G. Duchesne | David Joseph | Gillian Duchesne
[1] R Mohan,et al. Clinically relevant optimization of 3-D conformal treatments. , 1992, Medical physics.
[2] Annette Haworth,et al. Assessment of i-125 prostate implants by tumor bioeffect. , 2004, International journal of radiation oncology, biology, physics.
[3] R. Dale. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. , 1989, The British journal of radiology.
[4] X. Allen Li,et al. HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .
[5] David J Brenner,et al. Hypofractionation for prostate cancer radiotherapy--what are the issues? , 2003, International journal of radiation oncology, biology, physics.
[6] T E Schultheiss,et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. , 1997, International journal of radiation oncology, biology, physics.
[7] J D Fenwick,et al. Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression. , 1998, Physics in medicine and biology.
[8] J. Fowler,et al. On cold spots in tumor subvolumes. , 2002, Medical physics.
[9] Rick Chappell,et al. Is α/β for prostate tumors really low? , 2001 .
[10] A. Nahum,et al. The delta-TCP concept: a clinically useful measure of tumor control probability. , 1999, International journal of radiation oncology, biology, physics.
[11] M A Ebert,et al. Viability of the EUD and TCP concepts as reliable dose indicators. , 2000, Physics in medicine and biology.
[12] Warren D. D'Souza,et al. Is the α/β ratio for prostate cancer low? , 2001 .
[13] H. Kal,et al. HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .
[14] Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. , 2003, Physics in medicine and biology.
[15] D. Brenner,et al. In response to Drs. King and Mayo: low α/β values for prostate appear to be independent of modeling details1 , 2000 .
[16] J. Fowler,et al. Selective boosting of tumor subvolumes. , 2000, International journal of radiation oncology, biology, physics.
[17] T. Stamey,et al. Zonal Distribution of Prostatic Adenocarcinoma: Correlation with Histologic Pattern and Direction of Spread , 1988, The American journal of surgical pathology.
[18] R G Dale,et al. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.
[19] C Busch,et al. Modeling prostate cancer distributions. , 1999, Urology.
[20] J H Hendry,et al. A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity. , 1998, International journal of radiation oncology, biology, physics.
[21] M Goitein,et al. Intensity modulated therapy and inhomogeneous dose to the tumor: a note of caution. , 1996, International journal of radiation oncology, biology, physics.
[22] C C Ling,et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data. , 2001, International journal of radiation oncology, biology, physics.
[23] J. Fowler,et al. How low is the α/β ratio for prostate cancer? in regard to Wang et al., IJROBP 2003;55:194–203 , 2003 .
[24] A. Renshaw,et al. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? , 1999, International journal of radiation oncology, biology, physics.
[25] R. Stock,et al. A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.
[26] J. Battista,et al. The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer , 2003 .
[27] Jian Z. Wang,et al. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. , 2002, Medical physics.
[28] Jian Z. Wang,et al. Low α/β ratio for prostate cancer: in response to Dr. Fowler et al. , 2003 .
[29] D. Brenner,et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .
[30] M Goitein,et al. Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] S Webb,et al. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. , 1993, Physics in medicine and biology.
[32] Alexandru Daşu,et al. Should single or distributed parameters be used to explain the steepness of tumour control probability curves? , 2003, Physics in medicine and biology.
[33] D J Brenner,et al. Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.
[34] Duchesne Gm,et al. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. , 1999 .
[35] T. Akimoto,et al. Change in E-cadherin expression after X-ray irradiation of a human cancer cell line in vitro and in vivo. , 1998, International journal of radiation oncology, biology, physics.
[36] A. Niemierko. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. , 1997, Medical physics.
[37] H. Withers. Biological Aspects of Conformal Therapy , 2000, Acta oncologica.
[38] Sartaj Sahni,et al. Leaf sequencing algorithms for segmented multileaf collimation. , 2003, Physics in medicine and biology.
[39] A Brahme,et al. Biologically effective uniform dose (D) for specification, report and comparison of dose response relations and treatment plans. , 2001, Physics in medicine and biology.
[40] J. Fowler,et al. A comment on proliferation rates in human prostate cancer. , 2000, International journal of radiation oncology, biology, physics.
[41] S. Zavgorodni,et al. Modeling dose response in the presence of spatial variations in dose rate. , 2000, Medical physics.
[42] Jian Z. Wang,et al. The low α/β ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us? , 2003 .
[43] A Brahme,et al. Dosimetric precision requirements in radiation therapy. , 1984, Acta radiologica. Oncology.
[44] R G Dale,et al. Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.
[45] L. Anderson,et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .